Literature DB >> 26644992

Impact of Age, Race and Socio-economic Status on Temporal Trends in Late-Stage Prostate Cancer Diagnosis in Florida.

Pierre Goovaerts1, Hong Xiao2, Clement K Gwede3, Fei Tan4, Youjie Huang5, Georges Adunlin6, Askal Ali7.   

Abstract

Individual-level data from the Florida Cancer Data System (1981-2007) were analysed to explore temporal trends of prostate cancer late-stage diagnosis, and how they vary based on race, income and age. Annual census-tract rates were computed for two races (white and black) and two age categories (40-65, >65) before being aggregated according to census tract median household incomes. Joinpoint regression and a new disparity statistic were applied to model temporal trends and detect potential racial and socio-economic differences. Multi-dimensional scaling was used as an innovative way to visualize similarities among temporal trends in a 2-D space. Analysis of time-series indicated that late-stage diagnosis was generally more prevalent among blacks, for age category 40-64 compared to older patients covered by Medicare, and among classes of lower socio-economic status. Joinpoint regression also showed that the rate of decline in late-stage diagnosis was similar among older patients. For younger patients, the decline occurred at a faster pace for blacks with rates becoming similar to whites in the late 90s, in particular for higher incomes. Both races displayed distinct spatial patterns with higher rates of late-stage diagnosis in the Florida Panhandle for whites whereas high rates clustered in South-eastern Florida for blacks.

Entities:  

Keywords:  PSA screening; census tracts; disparities; joinpoint regression; socio-economic status

Year:  2015        PMID: 26644992      PMCID: PMC4669574          DOI: 10.1016/j.spasta.2015.07.002

Source DB:  PubMed          Journal:  Spat Stat


  33 in total

1.  Differences in socioeconomic status and survival among white and black men with prostate cancer.

Authors:  A S Robbins; A S Whittemore; D H Thom
Journal:  Am J Epidemiol       Date:  2000-02-15       Impact factor: 4.897

2.  Impact of age at diagnosis on prostate cancer treatment and survival.

Authors:  Seth K Bechis; Peter R Carroll; Matthew R Cooperberg
Journal:  J Clin Oncol       Date:  2010-12-06       Impact factor: 44.544

3.  The results of prostate carcinoma screening in the U.S. as reflected in the surveillance, epidemiology, and end results program.

Authors:  C R Smart
Journal:  Cancer       Date:  1997-11-01       Impact factor: 6.860

4.  Combining area-based and individual-level data in the geostatistical mapping of late-stage cancer incidence.

Authors:  Pierre Goovaerts
Journal:  Spat Spatiotemporal Epidemiol       Date:  2009 Oct-Dec

5.  Mortality results from a randomized prostate-cancer screening trial.

Authors:  Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Edward P Gelmann; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Richard B Hayes; Barnett S Kramer; Grant Izmirlian; Anthony B Miller; Paul F Pinsky; Philip C Prorok; John K Gohagan; Christine D Berg
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

6.  Explaining the race difference in prostate cancer stage at diagnosis.

Authors:  Beth A Jones; Wen-Liang Liu; Andre B Araujo; Stanislav V Kasl; Stephanie N Silvera; Hosanna Soler-Vilá; Mary G M Curnen; Robert Dubrow
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-09-30       Impact factor: 4.254

7.  Race, socioeconomic status and stage at diagnosis for five common malignancies.

Authors:  Kendra L Schwartz; Heather Crossley-May; Fawn D Vigneau; Karl Brown; Mousumi Banerjee
Journal:  Cancer Causes Control       Date:  2003-10       Impact factor: 2.506

8.  SELECTING THE NUMBER OF CHANGE-POINTS IN SEGMENTED LINE REGRESSION.

Authors:  Hyune-Ju Kim; Binbing Yu; Eric J Feuer
Journal:  Stat Sin       Date:  2009-05-01       Impact factor: 1.261

9.  PSA screening and deaths from prostate cancer after diagnosis--a population based analysis.

Authors:  Mitchell S Wachtel; Thomas Nelius; Allan L Haynes; Scott Dahlbeck; Werner de Riese
Journal:  Prostate       Date:  2013-05-06       Impact factor: 4.104

10.  Factors associated with time-to-treatment of prostate cancer in Florida.

Authors:  Hong Xiao; Fei Tan; Pierre Goovaerts; Georges Adunlin; Askal Ali; Youjie Huang; Clement K Gwede
Journal:  J Health Care Poor Underserved       Date:  2013-11
View more
  5 in total

Review 1.  Racial Differences in the Diagnosis and Treatment of Prostate Cancer.

Authors:  Giuliano Di Pietro; Ganna Chornokur; Nagi B Kumar; Chemar Davis; Jong Y Park
Journal:  Int Neurourol J       Date:  2016-11-22       Impact factor: 2.835

Review 2.  Racial disparities and considerations for active surveillance of prostate cancer.

Authors:  Song Jiang; Vikram Narayan; Christopher Warlick
Journal:  Transl Androl Urol       Date:  2018-04

3.  Application of Socio-Economic and Health Deprivation Indices to study the relationships between socio-economic status and disease onset and outcome in a metropolitan area subjected to aging, demographic fall and socio-economic crisis.

Authors:  Marina Vercelli; Roberto Lillini
Journal:  J Prev Med Hyg       Date:  2021-09-15

4.  Racial/ethnic disparities in de novo metastases sites and survival outcomes for patients with primary breast, colorectal, and prostate cancer.

Authors:  Tomi Akinyemiju; Swati Sakhuja; John Waterbor; Maria Pisu; Sean F Altekruse
Journal:  Cancer Med       Date:  2018-02-26       Impact factor: 4.452

5.  Clinical value of long noncoding RNA ZEB1 anti-sense1 in cancer patients: A meta-analysis.

Authors:  Sixiang Cheng; Shengyu Guo; Hairong He; Atipatsa Chiwanda Kaminga; Huilan Xu
Journal:  Medicine (Baltimore)       Date:  2020-07-31       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.